Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent ...

Roche reports positive phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity: Basel Wednesday, January 28, 2026, 10:00 Hrs [IST] Roche anno ...

FDA-approved oral GLP-1s match injectables in weight loss effectiveness with similar side effects and health benefits. There are differences, however.

The paper, titled, "Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study," was published in Obesity, the peer-reviewed ...

The new 12-month project extends a prior two-year award for which Habegger studied mechanisms of glucagon, Glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) and ...

By Tarun Sai Lomte From laboratory models to small human trials, a new review explores whether popular metabolic drugs could help curb alcohol, nicotine, and drug use, while underscoring how much ...

In this study, researchers matched patients using GLP-1RA therapy to those using aspirin to compare colorectal cancer incidence in each population.

Use of liraglutide or semaglutide therapy does not increase risk for thyroid cancer among patients with type 2 diabetes or obesity.

As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of obesity. They foresee a future of personalized obesity medicine similar to the ...

Did you know that weight-loss drugs might have the potential to heal the habit of substance abuse?In a recent study published ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP ...

A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p 54% of participants on the 24 mg dose achieved resolution of obesity (BMI C ...